RAPP news

Latest 2 stories · newest Oct 20, 2026

RAPP

Rapport Therapeutics Reports Positive Topline Results in Phase 2 Bipolar Mania Trial

Rapport Therapeutics announced statistically significant improvements in patients with bipolar mania treated with its drug RAP-219, marking a key milestone toward potential Phase 3 trials and establishing clinical proof-of-concept.

Other Oct 20, 2026 sentiment +0.60 SEC filing ↗

RAPP

Rapport Reports Q2 2026 Financials and Initiates RAP-219 Phase 3 Trials

Rapport Therapeutics reported Q2 2026 financials and announced the initiation of FOCUS 1 and 2 Phase 3 trials for RAP-219. The company maintains strong liquidity expected to fund operations into 2029. Analysis: This clinical advancement represents a significant milestone for the pipeline and validat…

Earnings Aug 5, 2026 sentiment +0.02 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same RAPP feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/RAPP/newsSTART FREE